The Legal Library section collates quality and in-depth reports on regulatory developments, court rulings and policy changes authored by India’s top law firms and consultants. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of law and policy.
ELP Update
On November 18, 2021 the Competition Commission of India released its report on 'Market Study on the Pharmaceutical Sector in India : Key Findings and Observations'.
The CCI, during its decade old enforcement regime, has mostly dealt with anti-competitive vertical restraints stemming from the distribution chain in the pharmaceutical industry.
The study focuses on several aspects of the pharmaceutical industry including distribution channels, role of trade associations, trade margins, online pharmacies and the prevalence of branded generic drugs in India and its implications for competition.
Given that the pharmaceutical sector is heavily regulated, the study aims to explore the areas of interface between regulation and competition with a view to ascertain CCI’s advocacy priorities. The key focus areas identified in the study were:
competition in generic drugs,
prevalence of branded generics in India and its implications for generic competition and drug prices,
pharmaceutical distribution landscape.
Click on the attachment to read the full report:
DISCLAIMER
This alert does not constitute legal advice and is for information purpose only. This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
As a Subscriber you get
Stories
RECOMMENDED FOR YOU
POPULAR